Each month, we analyse key data from the previous month’s concessionary products and the Category M tariff, to create Accord’s ‘Beyond the Headlines’.

This is created as an easy-to-understand summary of the trends that have impacted generic reimbursement, and how the figures fluctuate from one month to the next.

In this edition, we have expanded our monthly insights to demonstrate the impact that Apixaban has had to reimbursement, since its inclusion in the Category M tariff for July.

Impact of the July product additions

The addition of 14 new products to the July Category M tariff has had a noticeable impact on the overall average reimbursement price. The most significant addition is Apixaban 2.5mg & 5mg Tablets, which moved across from Category C. As demonstrated below, you can see that if this product were to be removed from the figures, the average reimbursement price would decrease from £3.37 to £3.05 for July:

You can read the full version of this month’s ‘Beyond the Headlines’ here.

Keep an eye on future editions of Beyond the Headlines, published monthly on the Partner Platform, where we will continue to track the Apixaban impact against new releases of the Category M tariff.